Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Rheumatoid Arthritis

  Free Subscription


Articles published in Ann Rheum Dis

Retrieve available abstracts of 237 articles:
HTML format



Single Articles


    December 2021
  1. BUGATTI S, De Stefano L, Balduzzi S, Greco MI, et al
    Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis.
    Ann Rheum Dis. 2021;80:1635-1638.
    PubMed    


    November 2021
  2. FELSON D, Lacaille D, LaValley MP, Aletaha D, et al
    Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment.
    Ann Rheum Dis. 2021 Nov 16. pii: annrheumdis-2021-221653.
    PubMed    


  3. SIDDLE HJ, Chapman LS, Mankia K, Zabalan C, et al
    Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies.
    Ann Rheum Dis. 2021 Nov 8. pii: annrheumdis-2021-221160.
    PubMed     Abstract available


  4. WINTHROP KL, Tanaka Y, Takeuchi T, Kivitz A, et al
    Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
    Ann Rheum Dis. 2021 Nov 5. pii: annrheumdis-2021-221051.
    PubMed     Abstract available


  5. TANAKA Y, Oba K, Takeuchi T
    Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al.
    Ann Rheum Dis. 2021;80:e173.
    PubMed    


  6. BERKHOUT LC, l'Ami MJ, Wolbink GJ, Rispens T, et al
    Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al.
    Ann Rheum Dis. 2021;80:e172.
    PubMed    


  7. CHEN MH, Lee IC, Chen MH, Hou MC, et al
    Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease.
    Ann Rheum Dis. 2021;80:1393-1399.
    PubMed     Abstract available


  8. NABI H, Georgiadis S, Loft AG, Hendricks O, et al
    Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
    Ann Rheum Dis. 2021;80:1400-1409.
    PubMed     Abstract available


    October 2021
  9. TAYLOR PC, Takeuchi T, Burmester GR, Durez P, et al
    Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Ann Rheum Dis. 2021 Oct 27. pii: annrheumdis-2021-221276.
    PubMed     Abstract available


  10. LI X, Tong X, Yeung WWY, Kuan P, et al
    Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong.
    Ann Rheum Dis. 2021 Oct 22. pii: annrheumdis-2021-221571.
    PubMed     Abstract available


  11. CHRISTENSEN IE, Lillegraven S, Mielnik P, Bakland G, et al
    Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
    Ann Rheum Dis. 2021 Oct 8. pii: annrheumdis-2021-221007.
    PubMed     Abstract available


  12. IBANEZ-COSTA A, Perez-Sanchez C, Patino-Trives AM, Luque-Tevar M, et al
    Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy.
    Ann Rheum Dis. 2021 Oct 8. pii: annrheumdis-2021-220308.
    PubMed     Abstract available


  13. WINTHROP KL, Nash P, Yamaoka K, Mysler E, et al
    Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
    Ann Rheum Dis. 2021 Oct 6. pii: annrheumdis-2021-220822.
    PubMed     Abstract available


  14. CAPELUSNIK D, Aletaha D
    Baseline predictors of different types of treatment success in rheumatoid arthritis.
    Ann Rheum Dis. 2021 Oct 4. pii: annrheumdis-2021-220853.
    PubMed     Abstract available


  15. FLOUDAS A, Neto N, Orr C, Canavan M, et al
    Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis.
    Ann Rheum Dis. 2021 Oct 1. pii: annrheumdis-2021-220458.
    PubMed     Abstract available


  16. MEEHAN GR, Thomas R, Al Khabouri S, Wehr P, et al
    Preclinical models of arthritis for studying immunotherapy and immune tolerance.
    Ann Rheum Dis. 2021;80:1268-1277.
    PubMed     Abstract available


  17. NIKIPHOROU E, Santos EJF, Marques A, Bohm P, et al
    2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis.
    Ann Rheum Dis. 2021;80:1278-1285.
    PubMed     Abstract available


    September 2021
  18. YOSHII I, Sawada N, Chijiwa T, Kokei S, et al
    Impact of sustaining SDAI remission for preventing incident of bone fragility fracture in patient with rheumatoid arthritis.
    Ann Rheum Dis. 2021 Sep 11. pii: annrheumdis-2021-221093.
    PubMed    


  19. MINOIA F, Ravelli A
    Response to 'Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease' by Wang et al.
    Ann Rheum Dis. 2021;80:e146.
    PubMed    


  20. WANG R, Li T, Ye S, Tan W, et al
    Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease.
    Ann Rheum Dis. 2021;80:e145.
    PubMed    


  21. OZEN G, Michaud K
    Response to: 'Medications associated with fracture risk in patients with rheumatoid arthritis' by Chen et al.
    Ann Rheum Dis. 2021;80:e141.
    PubMed    


  22. JONSSON R
    Henrik Sjogren (1899-1986): the syndrome and his legacy.
    Ann Rheum Dis. 2021;80:1108-1109.
    PubMed    


  23. MAASSEN JM, Dos Santos Sobrin R, Bergstra SA, Goekoop R, et al
    Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies.
    Ann Rheum Dis. 2021;80:1124-1129.
    PubMed     Abstract available


  24. LIOU YS, Lin TK, Chen HY, Jong GP, et al
    Medications associated with fracture risk in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2021;80:e140.
    PubMed    


    August 2021
  25. HECKERT SL, Bergstra SA, Matthijssen XME, Goekoop-Ruiterman YPM, et al
    Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course.
    Ann Rheum Dis. 2021 Aug 30. pii: annrheumdis-2021-220882.
    PubMed     Abstract available


  26. WANG Y, Xie X, Zhang C, Su M, et al
    Rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren's syndrome shared megakaryocyte expansion in peripheral blood.
    Ann Rheum Dis. 2021 Aug 30. pii: annrheumdis-2021-220066.
    PubMed     Abstract available


  27. WALLACE ZS, Sparks JA, Robinson PC, Machado PM, et al
    Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.
    Ann Rheum Dis. 2021 Aug 23. pii: annrheumdis-2021-220960.
    PubMed    


  28. GREMESE E, Ferraccioli G
    Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al.
    Ann Rheum Dis. 2021 Aug 23. pii: annrheumdis-2021-220932.
    PubMed    


  29. NAGY G, Roodenrijs NMT, Welsing PMJ, Kedves M, et al
    EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.
    Ann Rheum Dis. 2021 Aug 18. pii: annrheumdis-2021-220973.
    PubMed     Abstract available


  30. VAN VOLLENHOVEN RF, Tas SW, Nurmohamed MT
    Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry" by Sparks et al.
    Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-221146.
    PubMed    


  31. HOLTEN K, Paulshus Sundlisater N, Lillegraven S, Sexton J, et al
    Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment.
    Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-220750.
    PubMed     Abstract available


  32. SPARKS JA, Wallace ZS, Seet AM, Robinson PC, et al
    Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.
    Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-221157.
    PubMed    


  33. PLATZER A, Alasti F, Smolen JS, Aletaha D, et al
    Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables.
    Ann Rheum Dis. 2021 Aug 10. pii: annrheumdis-2021-220331.
    PubMed     Abstract available


  34. MANKIA K, Siddle HJ, Kerschbaumer A, Alpizar Rodriguez D, et al
    EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.
    Ann Rheum Dis. 2021 Aug 6. pii: annrheumdis-2021-220884.
    PubMed     Abstract available


  35. NASONOV E, Fatenejad S, Feist E, Ivanova M, et al
    Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.
    Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-219876.
    PubMed     Abstract available


  36. SPARKS JA
    Towards clinical significance of the MUC5B promoter variant and risk of rheumatoid arthritis-associated interstitial lung disease.
    Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-220856.
    PubMed    


  37. PALOMAKI A, Palotie A, Koskela J, Eklund KK, et al
    Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers.
    Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-220698.
    PubMed     Abstract available


    July 2021
  38. REDEKER I, Albrecht K, Kekow J, Burmester GR, et al
    Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register.
    Ann Rheum Dis. 2021 Jul 28. pii: annrheumdis-2021-220651.
    PubMed     Abstract available


  39. WOUTERS F, Maurits MP, van Boheemen L, Verstappen M, et al
    Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jul 20. pii: annrheumdis-2021-220546.
    PubMed     Abstract available



  40. Retraction: Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jul 6. pii: annrheumdis-2017-211351.
    PubMed    


  41. DUMOULIN QA, Matthijssen XME, Wouters F, Krijbolder DI, et al
    Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'.
    Ann Rheum Dis. 2021 Jul 5. pii: annrheumdis-2021-220511.
    PubMed    


  42. GESSL I, Aletaha D, Mandl P
    Response to: 'Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'' by Dumoulin et al.
    Ann Rheum Dis. 2021 Jul 5. pii: annrheumdis-2021-220922.
    PubMed    


  43. OCON AJ, Reed G, Pappas DA, Curtis JR, et al
    Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jul 2. pii: annrheumdis-2021-220577.
    PubMed     Abstract available


  44. WONG AY, MacKenna B, Morton CE, Schultze A, et al
    Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.
    Ann Rheum Dis. 2021;80:943-951.
    PubMed     Abstract available


  45. JOUSSE-JOULIN S, D'Agostino MA, Hocevar A, Naredo E, et al
    Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's sy
    Ann Rheum Dis. 2021;80:e112.
    PubMed    


  46. LAI SW, Kuo YH, Liao KF
    Chronic hydroxychloroquine exposure and the risk of Alzheimer's disease.
    Ann Rheum Dis. 2021;80:e105.
    PubMed    


  47. COIFFIER G, Martel A, Albert JD, Lescoat A, et al
    Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?
    Ann Rheum Dis. 2021;80:e111.
    PubMed    


  48. TRAVES PG, Murray B, Campigotto F, Galien R, et al
    JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Ann Rheum Dis. 2021;80:865-875.
    PubMed     Abstract available


    June 2021
  49. JAIN S, Dhir V
    Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'.
    Ann Rheum Dis. 2021 Jun 30. pii: annrheumdis-2021-220816.
    PubMed    


  50. STOUTEN V, Westhovens R, Pazmino S, De Cock D, et al
    Response to: 'Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'' by Jain and Dhir et al.
    Ann Rheum Dis. 2021 Jun 30. pii: annrheumdis-2021-220857.
    PubMed    


  51. ALBACH FN, Burmester GR, Biesen R
    Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
    Ann Rheum Dis. 2021 Jun 24. pii: annrheumdis-2021-220834.
    PubMed    


  52. SHIPA MRA, Amarnani R, Yeoh SA, Mainuddin MD, et al
    Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy.
    Ann Rheum Dis. 2021 Jun 23. pii: annrheumdis-2021-220642.
    PubMed    


  53. JAIN S, Dhir V, Aggarwal A, Gupta R, et al
    Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial.
    Ann Rheum Dis. 2021 Jun 10. pii: annrheumdis-2021-220512.
    PubMed     Abstract available


  54. PAULSHUS SUNDLISATER N, Aga AB, Olsen IC, Hammer HB, et al
    Joint tenderness and ultrasound inflammation in DMARD-naive patients with early rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jun 3. pii: annrheumdis-2021-220265.
    PubMed    


    May 2021
  55. SPARKS JA, Wallace ZS, Seet AM, Gianfrancesco MA, et al
    Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
    Ann Rheum Dis. 2021 May 28. pii: annrheumdis-2021-220418.
    PubMed     Abstract available


  56. JOHNSON TM, Sayles HR, Baker JF, George MD, et al
    Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.
    Ann Rheum Dis. 2021 May 28. pii: annrheumdis-2021-220125.
    PubMed     Abstract available


  57. D'ONOFRIO B, De Stefano L, Palermo BL, Xoxi B, et al
    Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19.
    Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220219.
    PubMed    


  58. LIN TK, Pan LF, Jong GP
    Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
    Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220453.
    PubMed    


  59. GONG Z, Zhang F
    Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
    Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220494.
    PubMed    


  60. ABTAHI S, Driessen JHM, Burden AM, Souverein PC, et al
    Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Gong and Zhang and Lin et al.
    Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220477.
    PubMed    


  61. TAKANASHI S, Kaneko Y, Takeuchi T
    Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis.
    Ann Rheum Dis. 2021 May 7. pii: annrheumdis-2021-220315.
    PubMed    



  62. Correction: Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
    Ann Rheum Dis. 2021;80:e83.
    PubMed    


  63. ROGIER C, van Dijk BT, Brouwer E, de Jong PHP, et al
    Realising early recognition of arthritis in times of increased telemedicine: the value of patient-reported swollen joints.
    Ann Rheum Dis. 2021;80:668-669.
    PubMed    


  64. SCHULZE-KOOPS H, Krueger K, Vallbracht I, Hasseli R, et al
    Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.
    Ann Rheum Dis. 2021;80:e67.
    PubMed    


  65. ROMAO VC, Cruz-Machado AR, Fonseca JE
    Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli et al.
    Ann Rheum Dis. 2021;80:e76.
    PubMed    


  66. ZHAO J, Pang R, Wu J, Guo Y, et al
    Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences.
    Ann Rheum Dis. 2021;80:e63.
    PubMed    


  67. MOENTADJ R, Wang Y, Bowerman K, Rehaume L, et al
    Streptococcus species enriched in the oral cavity of patients with RA are a source of peptidoglycan-polysaccharide polymers that can induce arthritis in mice.
    Ann Rheum Dis. 2021;80:573-581.
    PubMed     Abstract available


  68. KAJIO N, Takeshita M, Suzuki K, Kaneda Y, et al
    Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling.
    Ann Rheum Dis. 2021;80:651-659.
    PubMed     Abstract available


    April 2021
  69. ROONGTA R, Chattopadhyay A, Ghosh A
    Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'
    Ann Rheum Dis. 2021 Apr 27. pii: annrheumdis-2021-220479.
    PubMed    


  70. DERKSEN VFAM, van der Woude D
    Response to: 'Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'' by Roongta et al.
    Ann Rheum Dis. 2021 Apr 27. pii: annrheumdis-2021-220516.
    PubMed    


  71. INGEGNOLI F, Cincinelli G, Luppino AF, Favalli EG, et al
    Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy.
    Ann Rheum Dis. 2021 Apr 13. pii: annrheumdis-2021-220142.
    PubMed    


  72. MIYAZAKI Y, Nakano K, Nakayamada S, Kubo S, et al
    Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
    Ann Rheum Dis. 2021 Apr 7. pii: annrheumdis-2020-219699.
    PubMed     Abstract available


  73. XIE W, Huang H, Li G, Hao Y, et al
    Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020.
    Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2021-220112.
    PubMed     Abstract available


  74. STOUTEN V, Westhovens R, Pazmino S, De Cock D, et al
    Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.
    Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2020-219825.
    PubMed     Abstract available


  75. SO H, Cheng IT, Lau SL, Chow E, et al
    Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial.
    Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2021-219846.
    PubMed     Abstract available


    March 2021
  76. COSTENBADER KH, DiIorio M, Chu SH, Cui J, et al
    Circulating blood metabolite trajectories and risk of rheumatoid arthritis among military personnel in the Department of Defense Biorepository.
    Ann Rheum Dis. 2021 Mar 22. pii: annrheumdis-2020-219682.
    PubMed     Abstract available


  77. DERKSEN VFAM, Kissel T, Lamers-Karnebeek FBG, van der Bijl AE, et al
    Onset of rheumatoid arthritis after COVID-19: coincidence or connected?
    Ann Rheum Dis. 2021 Mar 1. pii: annrheumdis-2021-219859.
    PubMed    


    February 2021
  78. SMEELE HT, Roder E, Wintjes HM, Kranenburg-van Koppen LJ, et al
    Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PreCARA study.
    Ann Rheum Dis. 2021 Feb 10. pii: annrheumdis-2020-219547.
    PubMed     Abstract available


  79. ZHENG BK
    Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
    Ann Rheum Dis. 2021 Feb 8. pii: annrheumdis-2020-219797.
    PubMed    


  80. ABTAHI S, Driessen JHM, Burden AM, Souverein PC, et al
    Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Zheng.
    Ann Rheum Dis. 2021 Feb 8. pii: annrheumdis-2021-219856.
    PubMed    


  81. CIUREA A, Papagiannoulis E, Burki K, von Loga I, et al
    Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort.
    Ann Rheum Dis. 2021;80:238-241.
    PubMed     Abstract available


  82. WINTHROP KL, Brunton AE, Beekmann S, Polgreen P, et al
    SARS CoV-2 infection among patients using immunomodulatory therapies.
    Ann Rheum Dis. 2021;80:269-271.
    PubMed    


  83. MOISEEV S, Avdeev S, Brovko M, Yavorovskiy A, et al
    Rheumatic diseases in intensive care unit patients with COVID-19.
    Ann Rheum Dis. 2021;80:e16.
    PubMed    


  84. FAVALLI EG, Ingegnoli F, Cimaz R, Caporali R, et al
    What is the true incidence of COVID-19 in patients with rheumatic diseases?
    Ann Rheum Dis. 2021;80:e18.
    PubMed    


  85. ZERVOU MI, Goulielmos GN
    Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden'.
    Ann Rheum Dis. 2021 Feb 1. pii: annrheumdis-2021-219894.
    PubMed    


  86. MOLANDER V, Askling J
    Response to: 'Correspondence on 'Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden'' by Zervou et al.
    Ann Rheum Dis. 2021 Feb 1. pii: annrheumdis-2021-219920.
    PubMed    


  87. BEMIS EA, Demoruelle MK, Seifert JA, Polinski KJ, et al
    Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting.
    Ann Rheum Dis. 2021;80:154-161.
    PubMed     Abstract available


    January 2021
  88. COMBE B, Kivitz A, Tanaka Y, van der Heijde D, et al
    Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
    Ann Rheum Dis. 2021 Jan 27. pii: annrheumdis-2020-219214.
    PubMed     Abstract available


  89. MINISOLA S, Pepe J, Cipriani C
    Rheumatoid arthritis, bone and drugs: a dangerous interweave.
    Ann Rheum Dis. 2021 Jan 17. pii: annrheumdis-2020-219545.
    PubMed    


  90. LI K, Mo W, Wu L, Wu X, et al
    Novel autoantibodies identified in ACPA-negative rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jan 15. pii: annrheumdis-2020-218460.
    PubMed     Abstract available


  91. WESTHOVENS R, Rigby WFC, van der Heijde D, Ching DWT, et al
    Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
    Ann Rheum Dis. 2021 Jan 15. pii: annrheumdis-2020-219213.
    PubMed     Abstract available


  92. VAN MULLIGEN E, van der Helm-van Mil A, de Jong PHP
    Methotrexate prolongs TNF inhibitor survival, but only in autoantibody-positive rheumatoid arthritis: a validation study.
    Ann Rheum Dis. 2021 Jan 13. pii: annrheumdis-2020-219499.
    PubMed    


  93. GESSL I, Popescu M, Schimpl V, Supp G, et al
    Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis.
    Ann Rheum Dis. 2021 Jan 12. pii: annrheumdis-2020-218744.
    PubMed     Abstract available


  94. HA E, Bang SY, Lim J, Yun JH, et al
    Genetic variants shape rheumatoid arthritis-specific transcriptomic features in CD4(+) T cells through differential DNA methylation, explaining a substantial proportion of heritability.
    Ann Rheum Dis. 2021 Jan 12. pii: annrheumdis-2020-219152.
    PubMed     Abstract available


  95. BAKER JF, England BR, George M, Cannon G, et al
    Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis.
    Ann Rheum Dis. 2021 Jan 4. pii: annrheumdis-2020-219140.
    PubMed     Abstract available


  96. CAPECCHI PL, Lazzerini PE, Volterrani L, Mazzei MA, et al
    Antirheumatic agents in covid-19: is IL-6 the right target?
    Ann Rheum Dis. 2021;80:e2.
    PubMed    


  97. NASH P, Kerschbaumer A, Dorner T, Dougados M, et al
    Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
    Ann Rheum Dis. 2021;80:71-87.
    PubMed     Abstract available


  98. MEISSNER Y, Fischer-Betz R, Andreoli L, Costedoat-Chalumeau N, et al
    EULAR recommendations for a core data set for pregnancy registries in rheumatology.
    Ann Rheum Dis. 2021;80:49-56.
    PubMed     Abstract available


  99. MAGNOTTI F, Malsot T, Georgin-Lavialle S, Abbas F, et al
    Fast diagnostic test for familial Mediterranean fever based on a kinase inhibitor.
    Ann Rheum Dis. 2021;80:128-132.
    PubMed     Abstract available


  100. BOSSINI-CASTILLO L, Villanueva-Martin G, Kerick M, Acosta-Herrera M, et al
    Genomic Risk Score impact on susceptibility to systemic sclerosis.
    Ann Rheum Dis. 2021;80:118-127.
    PubMed     Abstract available


  101. MANGER B, Schett G
    Jan Mikulicz-Radecki (1850-1905): return of the surgeon.
    Ann Rheum Dis. 2021;80:8-10.
    PubMed    


    December 2020
  102. HA E, Bae SC, Kim K
    Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci.
    Ann Rheum Dis. 2020 Dec 11. pii: annrheumdis-2020-219065.
    PubMed     Abstract available


  103. ABTAHI S, Driessen JHM, Burden AM, Souverein PC, et al
    Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
    Ann Rheum Dis. 2020 Dec 11. pii: annrheumdis-2020-218758.
    PubMed     Abstract available


  104. PABLOS JL, Galindo M, Carmona L, Lledo A, et al
    Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
    Ann Rheum Dis. 2020;79:1544-1549.
    PubMed     Abstract available


  105. NUNO L, Novella Navarro M, Bonilla G, Franco-Gomez K, et al
    Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.
    Ann Rheum Dis. 2020;79:1659-1661.
    PubMed    


  106. TOES R, Pisetsky DS
    Response to: "How to communicate in science" by Klareskog et al.
    Ann Rheum Dis. 2020;79:e165.
    PubMed    


  107. OZEN G, Michaud K
    Response to: 'Association between proton pump inhibitors therapy and fracture risk in patients with rheumatoid arthritis' by Lai et al.
    Ann Rheum Dis. 2020;79:e157.
    PubMed    


  108. COUDERC M, Dubost JJ
    Response to: 'Ultrasonographic salivary gland evaluation in systemic sclerosis: is sicca syndrome secondary to an authentic overlap syndrome or another specific fibrotic manifestation of the disease?' by Coiffier et al.
    Ann Rheum Dis. 2020;79:e161.
    PubMed    


  109. COIFFIER G, Jousse-Joulin S, Cornec D, Garlantezec R, et al
    Ultrasonographic salivary gland evaluation in systemic sclerosis: is sicca syndrome secondary to an authentic overlap syndrome or another specific fibrotic manifestation of the disease?
    Ann Rheum Dis. 2020;79:e160.
    PubMed    


  110. PONTARINI E, Murray-Brown WJ, Croia C, Lucchesi D, et al
    Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjogren's syndrome with ectopic germinal centres and MALT lymphoma.
    Ann Rheum Dis. 2020;79:1588-1599.
    PubMed     Abstract available


  111. ADAMI G, Fassio A, Orsolini G, Giollo A, et al
    Effectiveness of influenza vaccine in TNF inhibitors treated patients: comment on the article by Burmester et al.
    Ann Rheum Dis. 2020;79:e166.
    PubMed    


    November 2020
  112. PAPPAS DA, St John G, Etzel CJ, Fiore S, et al
    Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US
    Ann Rheum Dis. 2020 Nov 11. pii: annrheumdis-2020-218907.
    PubMed    


  113. ZHENG W, Leong PY, Wei JC
    Correspondence to 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry stu
    Ann Rheum Dis. 2020 Nov 11. pii: annrheumdis-2020-218865.
    PubMed    


  114. BOERS M
    Patient global assessment to define remission in rheumatoid arthritis:quo vadis?
    Ann Rheum Dis. 2020 Nov 6. pii: annrheumdis-2020-218802.
    PubMed    


  115. FLEISCHMANN RM, Blanco R, Hall S, Thomson GTD, et al
    Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2020 Nov 4. pii: annrheumdis-2020-218412.
    PubMed     Abstract available


  116. ANDREEV D, Liu M, Kachler K, Llerins Perez M, et al
    Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis.
    Ann Rheum Dis. 2020 Nov 4. pii: annrheumdis-2020-218902.
    PubMed     Abstract available


  117. WOUTERS F, Niemantsverdriet E, Salioska N, Dorjee AL, et al
    Do autoantibody-responses mature between presentation with arthralgia suspicious for progression to rheumatoid arthritis and development of clinically apparent inflammatory arthritis? A longitudinal serological study.
    Ann Rheum Dis. 2020 Nov 3. pii: annrheumdis-2020-218221.
    PubMed    


  118. TSUCHIYA H, Ota M, Sumitomo S, Ishigaki K, et al
    Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis.
    Ann Rheum Dis. 2020 Nov 2. pii: annrheumdis-2020-218189.
    PubMed     Abstract available


  119. JONG GP, Pan LF, Lin TK, Chen HY, et al
    Correspondence on 'Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease'.
    Ann Rheum Dis. 2020 Nov 2. pii: annrheumdis-2020-219201.
    PubMed    


  120. LOGSTRUP BB, Olesen KKW, Masic D, Gyldenkerne C, et al
    Response to 'Correspondence on 'Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease" by Jong et al.
    Ann Rheum Dis. 2020 Nov 2. pii: annrheumdis-2020-219231.
    PubMed    


  121. FREITES NUNEZ DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, et al
    Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.
    Ann Rheum Dis. 2020;79:1393-1399.
    PubMed     Abstract available


  122. RUSCITTI P, Berardicurti O, Barile A, Cipriani P, et al
    Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?
    Ann Rheum Dis. 2020;79:1515-1516.
    PubMed    


  123. DORNER T
    Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
    Ann Rheum Dis. 2020;79:1389-1392.
    PubMed    


  124. RIVIERE E, Pascaud J, Tchitchek N, Boudaoud S, et al
    Salivary gland epithelial cells from patients with Sjogren's syndrome induce B-lymphocyte survival and activation.
    Ann Rheum Dis. 2020;79:1468-1477.
    PubMed     Abstract available


    October 2020
  125. COHEN SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, et al
    Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
    Ann Rheum Dis. 2020 Oct 28. pii: annrheumdis-2020-218510.
    PubMed     Abstract available


  126. WINTHROP KL, Citera G, Gold D, Henrohn D, et al
    Age-based (<65 vs >/=65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.
    Ann Rheum Dis. 2020 Oct 12. pii: annrheumdis-2020-218992.
    PubMed    


  127. ENGLAND BR, Roul P, Yang Y, Sayles H, et al
    Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015.
    Ann Rheum Dis. 2020 Oct 8. pii: annrheumdis-2020-218282.
    PubMed     Abstract available


  128. MOLANDER V, Bower H, Frisell T, Askling J, et al
    Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden.
    Ann Rheum Dis. 2020 Oct 8. pii: annrheumdis-2020-218419.
    PubMed     Abstract available


  129. FERREIRA RJO, Welsing PMJ, Jacobs JWG, Gossec L, et al
    Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients.
    Ann Rheum Dis. 2020 Oct 6. pii: annrheumdis-2020-217171.
    PubMed     Abstract available


  130. NAGY G, Roodenrijs NM, Welsing PM, Kedves M, et al
    EULAR definition of difficult-to-treat rheumatoid arthritis.
    Ann Rheum Dis. 2020 Oct 1. pii: annrheumdis-2020-217344.
    PubMed     Abstract available


  131. CHENG Z, Do T, Mankia K, Meade J, et al
    Dysbiosis in the oral microbiomes of anti-CCP positive individuals at risk of developing rheumatoid arthritis.
    Ann Rheum Dis. 2020 Oct 1. pii: annrheumdis-2020-216972.
    PubMed     Abstract available


  132. POPPELAARS PBM, van Tuyl LHD, Boers M
    Mortality has improved in RA, but we must remain vigilant. Response to: 'Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA' by Matthijssen et al.
    Ann Rheum Dis. 2020;79:e125.
    PubMed    


  133. MATTHIJSSEN XM, Huizinga TW, Niemantsverdriet E, van der Helm-van Mil AH, et al
    Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA.
    Ann Rheum Dis. 2020;79:e124.
    PubMed    


  134. COUDERC M, Tournadre A, Mathieu S, Pereira B, et al
    Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjogren's syndrome?
    Ann Rheum Dis. 2020;79:e137.
    PubMed    


  135. NIKPOUR M
    Sicca: an important manifestation of damage in systemic sclerosis (SSc) and SSc-overlap syndromes. Response to 'Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjogren's syndrome?' by Coudre
    Ann Rheum Dis. 2020;79:e138.
    PubMed    


  136. STRANGFELD A, Burmester GR
    Methotrexate: what are the true risks of treatment?
    Ann Rheum Dis. 2020;79:1267-1268.
    PubMed    


    September 2020
  137. ZHANG B, Wang Y, Yuan Y, Sun J, et al
    In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells.
    Ann Rheum Dis. 2020 Sep 30. pii: annrheumdis-2020-217844.
    PubMed     Abstract available


  138. HE P, Zhu H, Wu LF, Deng FY, et al
    Response to 'Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'' by Wang and Niu.
    Ann Rheum Dis. 2020 Sep 22. pii: annrheumdis-2020-218934.
    PubMed    


  139. WANG H, Niu L
    Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'.
    Ann Rheum Dis. 2020 Sep 22. pii: annrheumdis-2020-218825.
    PubMed    


  140. LORTHOLARY O, Fernandez-Ruiz M, Baddley JW, Manuel O, et al
    Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020.
    Ann Rheum Dis. 2020 Sep 22. pii: annrheumdis-2020-217092.
    PubMed     Abstract available


  141. ORMSETH MJ, Wu Q, Zhao S, Allen RM, et al
    Circulating microbial small RNAs are altered in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2020 Sep 21. pii: annrheumdis-2020-217589.
    PubMed     Abstract available


  142. CACCIAPAGLIA F, Manfredi A, Erre G, Piga M, et al
    Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry' by Gianfrancesco M et al. The impact of cardiovascular c
    Ann Rheum Dis. 2020 Sep 15. pii: annrheumdis-2020-218813.
    PubMed    


  143. VAN MULLIGEN E, Weel AE, Kuijper TM, Denissen NHAM, et al
    Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial.
    Ann Rheum Dis. 2020 Sep 9. pii: annrheumdis-2020-217528.
    PubMed     Abstract available


  144. SHARMA C, Whittle S, Haghighi PD, Burstein F, et al
    Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis.
    Ann Rheum Dis. 2020 Sep 3. pii: annrheumdis-2020-217333.
    PubMed     Abstract available


  145. MEISTERS R, Putrik P, Ramiro S, Hifinger M, et al
    EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries.
    Ann Rheum Dis. 2020 Sep 1. pii: annrheumdis-2020-217520.
    PubMed     Abstract available


  146. PABLOS JL, Abasolo L, Alvaro-Gracia JM, Blanco FJ, et al
    Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.
    Ann Rheum Dis. 2020;79:1170-1173.
    PubMed     Abstract available


  147. BELLIER A, Romand X, Baillet A
    Response to: 'Response to: 'Alcohol is not the missing link between Porphyromonas gingivalis related periodontitis and radiologic progression in early Rheumatoid arthritis' by Hillion et al' by Marotte and Paul.
    Ann Rheum Dis. 2020;79:e109.
    PubMed    


  148. CHANDRAN V, Cook RJ, Gladman DD
    Response to: 'Can biomarkers differentiate psoriatic arthritis from osteoarthritis?' by Tian et al.
    Ann Rheum Dis. 2020;79:e113.
    PubMed    


  149. MAROTTE H, Paul S
    Response to: 'Alcohol is not the missing link between Porphyromonas gingivalis related periodontitis and radiologic progression in early Rheumatoid arthritis' by Hillion et al.
    Ann Rheum Dis. 2020;79:e108.
    PubMed    


  150. OZEN G, Michaud K
    Response to: 'Association of proton pump inhibitors with fracture risk in patients with rheumatoid arthritis' by Sugiyama.
    Ann Rheum Dis. 2020;79:e111.
    PubMed    


  151. JENNING M, Marklein B, Ytterberg J, Zubarev RA, et al
    Bacterial citrullinated epitopes generated by Porphyromonas gingivalis infection-a missing link for ACPA production.
    Ann Rheum Dis. 2020;79:1194-1202.
    PubMed     Abstract available


  152. CHEVALIER K, Belkhir R, Seror R, Mariette X, et al
    Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjogren syndrome refractory to rituximab alone.
    Ann Rheum Dis. 2020;79:1257-1259.
    PubMed    


    August 2020
  153. LENG RX, Di DS, Ni J, Wu XX, et al
    Identification of new susceptibility loci associated with rheumatoid arthritis.
    Ann Rheum Dis. 2020 Aug 31. pii: annrheumdis-2020-217351.
    PubMed     Abstract available


  154. PLEIN S, Erhayiem B, Fent G, Horton S, et al
    Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis.
    Ann Rheum Dis. 2020 Aug 28. pii: annrheumdis-2020-217653.
    PubMed     Abstract available


  155. WINTHROP KL, Harigai M, Genovese MC, Lindsey S, et al
    Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
    Ann Rheum Dis. 2020 Aug 11. pii: annrheumdis-2019-216852.
    PubMed     Abstract available


  156. MEASE P, Charles-Schoeman C, Cohen S, Fallon L, et al
    Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
    Ann Rheum Dis. 2020 Aug 5. pii: annrheumdis-2019-216761.
    PubMed     Abstract available


  157. SINGER ME, Kaelber DC, Antonelli MJ
    Hydroxychloroquin ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis.
    Ann Rheum Dis. 2020 Aug 5. pii: annrheumdis-2020-218500.
    PubMed    


  158. KEDOR C, Listing J, Zernicke J, Weiss A, et al
    Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.
    Ann Rheum Dis. 2020;79:1090-1097.
    PubMed     Abstract available


  159. VIVEKANANTHAM A, Belousov M, Hassan L, Nenadic G, et al
    Patient discussions of glucocorticoid-related side effects within an online health community forum.
    Ann Rheum Dis. 2020;79:1121-1122.
    PubMed    


    July 2020
  160. SHIRAI Y, Honda S, Ikari K, Kanai M, et al
    Association of the RPA3-UMAD1 locus with interstitial lung diseases complicated with rheumatoid arthritis in Japanese.
    Ann Rheum Dis. 2020 Jul 31. pii: annrheumdis-2020-217256.
    PubMed     Abstract available


  161. PETHOE-SCHRAMM A, Devenport J, Reiss W
    Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'.
    Ann Rheum Dis. 2020 Jul 31. pii: annrheumdis-2020-218365.
    PubMed    


  162. SHAFRAN IH, Alasti F, Smolen JS, Aletaha D, et al
    Response to: 'Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'' by Pethoe-Schramm et al.
    Ann Rheum Dis. 2020 Jul 31. pii: annrheumdis-2020-218403.
    PubMed    


  163. CHERLIN S, Lewis MJ, Plant D, Nair N, et al
    Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between IL18RAP expression and treatment response.
    Ann Rheum Dis. 2020 Jul 30. pii: annrheumdis-2020-217204.
    PubMed     Abstract available


  164. KWON YC, Lim J, Bang SY, Ha E, et al
    Genome-wide association study in a Korean population identifies six novel susceptibility loci for rheumatoid arthritis.
    Ann Rheum Dis. 2020 Jul 28. pii: annrheumdis-2020-217663.
    PubMed     Abstract available


  165. PAPPAS DA, St John G, Etzel CJ, Fiore S, et al
    Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
    Ann Rheum Dis. 2020 Jul 21. pii: annrheumdis-2020-217209.
    PubMed     Abstract available


  166. SANCHEZ-PIEDRA C, Diaz-Torne C, Manero J, Pego-Reigosa JM, et al
    Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
    Ann Rheum Dis. 2020;79:988-990.
    PubMed    


  167. GIANFRANCESCO M, Hyrich KL, Al-Adely S, Carmona L, et al
    Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
    Ann Rheum Dis. 2020;79:859-866.
    PubMed     Abstract available


  168. VAN MULLIGEN E, Hazes JMW, Weel AEAM, de Jong PHP, et al
    Response to: 'TARA Study: a new perspective on tapering drugs in RA' by Mishra et al.
    Ann Rheum Dis. 2020;79:e80.
    PubMed    


  169. MISHRA D, Chattopadhyay A, Jain S, Dhir V, et al
    TARA study: a new perspective on tapering drugs in RA.
    Ann Rheum Dis. 2020;79:e79.
    PubMed    


  170. LEBLOND A, Pezet S, Cauvet A, Casas C, et al
    Implication of the deacetylase sirtuin-1 on synovial angiogenesis and persistence of experimental arthritis.
    Ann Rheum Dis. 2020;79:891-900.
    PubMed     Abstract available


  171. DI MATTEO A, Mankia K, Duquenne L, Cipolletta E, et al
    Ultrasound erosions in the feet best predict progression to inflammatory arthritis in anti-CCP positive at-risk individuals without clinical synovitis.
    Ann Rheum Dis. 2020;79:901-907.
    PubMed     Abstract available


  172. ULIJN E, den Broeder N, Wientjes M, van Herwaarden N, et al
    Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ann Rheum Dis. 2020;79:867-873.
    PubMed     Abstract available


    June 2020
  173. COSTELLO RE, Humphreys JH, Winthrop KL, Dixon WG, et al
    Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2020 Jun 26. pii: annrheumdis-2020-217255.
    PubMed    


  174. SANTOS-MORENO P, Chavez-Chavez J, Hernandez-Zambrano SM, Rivera-Triana DP, et al
    Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic.
    Ann Rheum Dis. 2020 Jun 25. pii: annrheumdis-2020-218165.
    PubMed    


  175. BOZZALLA CASSIONE E, Zanframundo G, Biglia A, Codullo V, et al
    Response to: 'Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic' by Santos-Moreno et al.
    Ann Rheum Dis. 2020 Jun 25. pii: annrheumdis-2020-218193.
    PubMed    


  176. FIGUEROA-PARRA G, Gamboa-Alonso CM, Galarza-Delgado DA
    Challenges and opportunities in telerheumatology in the COVID-19 era. Response to: 'Online management of rheumatoid arthritis during COVID-19 pandemic' by Zhang et al.
    Ann Rheum Dis. 2020 Jun 19. pii: annrheumdis-2020-217631.
    PubMed    


  177. XU X, He X, Yang Y, Yao M, et al
    Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-gamma treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis.
    Ann Rheum Dis. 2020 Jun 19. pii: annrheumdis-2020-217798.
    PubMed     Abstract available


  178. CHRISTENSEN ABH, Just SA, Andersen JKH, Savarimuthu TR, et al
    Applying cascaded convolutional neural network design further enhances automatic scoring of arthritis disease activity on ultrasound images from rheumatoid arthritis patients.
    Ann Rheum Dis. 2020 Jun 5. pii: annrheumdis-2019-216636.
    PubMed     Abstract available



  179. Correction: Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).
    Ann Rheum Dis. 2020;79:e77.
    PubMed    


  180. FIGUEROA-PARRA G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, et al
    Are my patients with rheumatic diseases at higher risk of COVID-19?
    Ann Rheum Dis. 2020;79:839-840.
    PubMed    


  181. VAN MULLIGEN E, Weel AE, Hazes JM, van der Helm-van Mil A, et al
    Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial.
    Ann Rheum Dis. 2020 Jun 1. pii: annrheumdis-2020-217485.
    PubMed     Abstract available


  182. VORDENBAUMEN S, Brinks R, Richter JG, Albrecht K, et al
    Response to 'What rheumatologist should know about Fabry disease' by Moiseev et al.
    Ann Rheum Dis. 2020;79:e72.
    PubMed    


  183. MOISEEV S, Karovaikina E, Novikov PI, Ismailova D, et al
    What rheumatologist should know about Fabry disease.
    Ann Rheum Dis. 2020;79:e71.
    PubMed    


  184. DAMOISEAUX J, Andrade LEC
    Response to: 'Antinuclear antibodies: mitotic patterns and their clinical associations' by Betancur and Gomez-Puerta.
    Ann Rheum Dis. 2020;79:e64.
    PubMed    


  185. ZHU FX, Huang JY, Ye Z, Wen QQ, et al
    Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study.
    Ann Rheum Dis. 2020;79:793-799.
    PubMed     Abstract available


  186. HU Q, Wang M, Jia J, Teng J, et al
    Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China.
    Ann Rheum Dis. 2020;79:842-844.
    PubMed    


  187. NASH P
    2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews.
    Ann Rheum Dis. 2020;79:679-680.
    PubMed    


    May 2020
  188. KITAMURA K, Shionoya H, Terato K, Suzuki S, et al
    Comment on: 'Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population' by Kishikawa et al.
    Ann Rheum Dis. 2020 May 29. pii: annrheumdis-2020-217808.
    PubMed    


  189. KISHIKAWA T, Maeda Y, Nii T, Okada Y, et al
    The positive correlation between Porphyromonas gingivalis and Prevotella spp. Response to: 'Comment on 'Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population' by Kishikawa et al
    Ann Rheum Dis. 2020 May 29. pii: annrheumdis-2020-217897.
    PubMed    


  190. LOGSTRUP BB, Olesen KKW, Masic D, Gyldenkerne C, et al
    Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease.
    Ann Rheum Dis. 2020 May 29. pii: annrheumdis-2020-217154.
    PubMed     Abstract available


  191. CASTELLANOS-MOREIRA R, Rodriguez-Garcia SC, Haro I, Sanmarti R, et al
    Relationship between rheumatoid arthritis and interstitial lung disease is a 'two-way street'. Response to: 'Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a 'mix-and-match' approach' by Alunno et al.
    Ann Rheum Dis. 2020 May 28. pii: annrheumdis-2020-217432.
    PubMed    


  192. GREENWOOD M, Shipa M, Yeoh SA, Roussou E, et al
    Methotrexate reduces withdrawal rates of TNF inhibitors due to ineffectiveness in rheumatoid arthritis but only in patients who are seropositive.
    Ann Rheum Dis. 2020 May 28. pii: annrheumdis-2020-217725.
    PubMed    


  193. EMERY P, Burmester GR, Naredo E, Sinigaglia L, et al
    Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
    Ann Rheum Dis. 2020 May 13. pii: annrheumdis-2020-217246.
    PubMed     Abstract available


  194. ZHAO SS, Lyu H, Solomon DH, Yoshida K, et al
    Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework.
    Ann Rheum Dis. 2020 May 7. pii: annrheumdis-2020-217200.
    PubMed     Abstract available


  195. SHAFRAN IH, Alasti F, Smolen JS, Aletaha D, et al
    Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab.
    Ann Rheum Dis. 2020 May 5. pii: annrheumdis-2019-215987.
    PubMed     Abstract available


  196. GUO J, Zhang T, Li X, Cao H, et al
    Response to: 'Questions on 'Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population' by Guo et al' by Regueiro and Gonzalez.
    Ann Rheum Dis. 2020 May 5. pii: annrheumdis-2020-217064.
    PubMed    


  197. WESTERLIND H, Holmqvist M, Ljung L, Frisell T, et al
    Response to: 'Inflammatory and non-inflammatory triggers of acute coronary syndromes' by Eyuboglu.
    Ann Rheum Dis. 2020;79:e50.
    PubMed    


  198. EYUBOGLU M
    Inflammatory and non-inflammatory triggers of acute coronary syndromes.
    Ann Rheum Dis. 2020;79:e49.
    PubMed    


  199. KOPP TI, Delcoigne B, Arkema EV, Jacobsen RK, et al
    Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
    Ann Rheum Dis. 2020;79:566-572.
    PubMed     Abstract available


    April 2020
  200. ZHANG Y, Wang J, Zhao L, Xiao J, et al
    Online management of rheumatoid arthritis during COVID-19 pandemic.
    Ann Rheum Dis. 2020 Apr 27. pii: annrheumdis-2020-217548.
    PubMed    


  201. ATTIPOE L, Chaabo K, Wajed J, Hassan FU, et al
    Imaging neoangiogenesis in rheumatoid arthritis (INIRA): whole-body synovial uptake of a (99m)Tc-labelled RGD peptide is highly correlated with power Doppler ultrasound.
    Ann Rheum Dis. 2020 Apr 23. pii: annrheumdis-2020-217228.
    PubMed    



  202. Correction: Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population.
    Ann Rheum Dis. 2020 Apr 20. pii: annrheumdis-2018-214725.
    PubMed    


  203. BUGATTI S, De Stefano L, Favalli EG, Caporali R, et al
    Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis.
    Ann Rheum Dis. 2020 Apr 20. pii: annrheumdis-2020-217488.
    PubMed    


  204. HSIEH PH, Wu O, Geue C, McIntosh E, et al
    Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.
    Ann Rheum Dis. 2020 Apr 3. pii: annrheumdis-2019-216243.
    PubMed     Abstract available


  205. PAZMINO S, Boonen A, Stouten V, De Cock D, et al
    Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.
    Ann Rheum Dis. 2020 Apr 2. pii: annrheumdis-2019-216874.
    PubMed     Abstract available


  206. ALUNNO A, Bistoni O, Bonifacio AF, Gerli R, et al
    Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a 'mix-and-match' approach?
    Ann Rheum Dis. 2020 Apr 2. pii: annrheumdis-2020-217410.
    PubMed    


  207. AUNGIER S, Cartwright AJ, Schwenzer A, Marshall J, et al
    Response to: 'Potential roles for tenascin in (very) early diagnosis and treatment of rheumatoid arthritis' by Cutolo et al.
    Ann Rheum Dis. 2020;79:e43.
    PubMed    


  208. LAUPER K, Courvoisier DS, Gabay C
    Response to: 'When binary and continuous responses disagree' by Dr Ouyang.
    Ann Rheum Dis. 2020;79:e39.
    PubMed    


  209. OUYANG F
    When binary and continuous responses disagree.
    Ann Rheum Dis. 2020;79:e38.
    PubMed    


  210. SUN JL, Zhang HZ, Liu SY, Lian CF, et al
    Elevated EPSTI1 promote B cell hyperactivation through NF-kappaB signalling in patients with primary Sjogren's syndrome.
    Ann Rheum Dis. 2020;79:518-524.
    PubMed     Abstract available


  211. GODMANN L, Bollmann M, Korb-Pap A, Konig U, et al
    Antibody-mediated inhibition of syndecan-4 dimerisation reduces interleukin (IL)-1 receptor trafficking and signalling.
    Ann Rheum Dis. 2020;79:481-489.
    PubMed     Abstract available


  212. KISSEL T, Reijm S, Slot LM, Cavallari M, et al
    Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications.
    Ann Rheum Dis. 2020;79:472-480.
    PubMed     Abstract available


  213. EMERY P, Horton S, Dumitru RB, Naraghi K, et al
    Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial.
    Ann Rheum Dis. 2020;79:464-471.
    PubMed     Abstract available


    March 2020
  214. KISHIKAWA T, Maeda Y, Nii T, Okada Y, et al
    Response to: 'Can sexual dimorphism in rheumatoid arthritis be attributed to the different abundance of Gardnerella?' by Liu et al.
    Ann Rheum Dis. 2020 Mar 25. pii: annrheumdis-2020-217264.
    PubMed    


  215. PISETSKY DS, Spencer DM, Lipsky PE, Rovin BH, et al
    Response to: 'Can solid-phase assays replace immunofluorescence for ANA screening?' by Bizzaro.
    Ann Rheum Dis. 2020;79:e33.
    PubMed    


  216. BERGSTRA SA, Allaart CF, Landewe RBM
    Response to: 'Catching the falling star: points to consider when using propensity scores' by Ouyang et al.
    Ann Rheum Dis. 2020;79:e27.
    PubMed    


  217. OUYANG F
    Catching the falling star: points to consider when using propensity scores.
    Ann Rheum Dis. 2020;79:e26.
    PubMed    


  218. MANKIA K, D'Agostino MA, Emery P
    Response to: 'Ultrasound findings in palindromic rheumatism' by Sanmarti et al.
    Ann Rheum Dis. 2020;79:e31.
    PubMed    


  219. SANMARTI R, Ramirez J, Castellanos-Moreira R, Cabrera-Villalba SR, et al
    Ultrasound findings in palindromic rheumatism.
    Ann Rheum Dis. 2020;79:e30.
    PubMed    


  220. VAN DER HELM-VAN MIL A, Landewe RBM
    The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA.
    Ann Rheum Dis. 2020;79:312-315.
    PubMed     Abstract available


  221. ATTUR M, Zhou H, Samuels J, Krasnokutsky S, et al
    Interleukin 1 receptor antagonist (IL1RN) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease.
    Ann Rheum Dis. 2020;79:400-407.
    PubMed     Abstract available


    February 2020
  222. MOFORS J, Bjork A, Smedby KE, Kvarnstrom M, et al
    Increased risk of multiple myeloma in primary Sjogren's syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies.
    Ann Rheum Dis. 2020;79:307-308.
    PubMed    


  223. KANEKO Y, Kameda H, Ikeda K, Ishii T, et al
    Response to: 'Some concerns from Turkey' by Bilgin et al.
    Ann Rheum Dis. 2020;79:e16.
    PubMed    


  224. BILGIN E, Ozarli I, Kilic L, Bolek EC, et al
    Some concerns from Turkey.
    Ann Rheum Dis. 2020;79:e15.
    PubMed    


    January 2020
  225. VAN DEN HOOGEN LL, van der Heijden EHM, Hillen MR, Mertens JS, et al
    Galectin-9 reflects the interferon signature and correlates with disease activity in systemic autoimmune diseases. Response to: 'Biomarkers: to be or not to be' by Yavuz and Ronnblom.
    Ann Rheum Dis. 2020;79:e9.
    PubMed    


  226. RAMOS-CASALS M, Brito-Zeron P, Bombardieri S, Bootsma H, et al
    EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies.
    Ann Rheum Dis. 2020;79:3-18.
    PubMed     Abstract available


  227. WINTHROP KL, Weinblatt ME, Bathon J, Burmester GR, et al
    Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.
    Ann Rheum Dis. 2020;79:88-93.
    PubMed     Abstract available


  228. LEE AY, Chataway T, Gordon TP, Wang JJ, et al
    Molecular typing of cryoglobulins by mass spectrometry.
    Ann Rheum Dis. 2020;79:163-164.
    PubMed    


  229. TAKESHITA M, Suzuki K, Kaneda Y, Yamane H, et al
    Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.
    Ann Rheum Dis. 2020;79:150-158.
    PubMed     Abstract available


  230. LI Z, Liu HL, Chen J, Zeng T, et al
    Both HLA class I and II regions identified as genome-wide significant susceptibility loci for adult-onset Still's disease in Chinese individuals.
    Ann Rheum Dis. 2020;79:161-163.
    PubMed    


  231. BECH B, Primdahl J, van Tubergen A, Voshaar M, et al
    2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis.
    Ann Rheum Dis. 2020;79:61-68.
    PubMed     Abstract available


  232. PACHECO Y, Monsalve DM, Acosta-Ampudia Y, Rojas C, et al
    Antinuclear autoantibodies: discordance among four different assays.
    Ann Rheum Dis. 2020;79:e6.
    PubMed    


  233. KILTZ U, Kiefer D, Braun J, Schiffrin EJ, et al
    Prolonged treatment with Tadekinig alfa in adult-onset Still's disease.
    Ann Rheum Dis. 2020;79:e10.
    PubMed    


    October 2019
  234. WOUTERS F, van der Giesen FJ, Matthijssen XME, Niemantsverdriet E, et al
    Difficulties making a fist in clinically suspect arthralgia: an easy applicable phenomenon predictive for RA that is related to flexor tenosynovitis.
    Ann Rheum Dis. 2019;78:1438-1439.
    PubMed    


    September 2019
  235. BLUETT J, Riba-Garcia I, Verstappen SMM, Wendling T, et al
    Development and validation of a methotrexate adherence assay.
    Ann Rheum Dis. 2019;78:1192-1197.
    PubMed     Abstract available


  236. LOH C, Park SH, Lee A, Yuan R, et al
    TNF-induced inflammatory genes escape repression in fibroblast-like synoviocytes: transcriptomic and epigenomic analysis.
    Ann Rheum Dis. 2019;78:1205-1214.
    PubMed     Abstract available


  237. DERVIEUX T, Kremer JM, Weinblatt ME
    Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.
    Ann Rheum Dis. 2019;78:1285-1286.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: